Short Courses

The 2020 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop will offer 10 half-day short courses Tuesday, September 22, and Wednesday, September 23. You may register for a maximum of one free course each day. If you would like to attend additional courses, you may do so for an additional $75 per course. Please email if you wish to purchase additional courses. Space is limited, so register as soon as possible.

Tuesday, September 22

Morning Short Course

10:00 a.m. – 1:30 p.m.

SC1: A Gentle Introduction to Causal Inference in View of the ICH E9 Addendum on Estimands
Dong Xi, Novartis Pharmaceuticals; Heinz Schmidli, Novartis Pharma AG; and Björn Bornkamp, Novartis Pharma AG

Afternoon Short Courses

2:00 p.m. – 5:30 p.m.

SC2: Artificial Intelligence for Drug Development, Precision Medicine, and Health Care
Mark Chang, Boston University, and Sandeep Menon, Pfizer Inc.

SC3: Bayesian Designs for Phase I-II Clinical Trials
Peter Thall, The University of Texas MD Anderson Cancer Center, and Ying Yuan, The University of Texas MD Anderson Cancer Center

SC4: Causal Inference for Real-World Evidence: Propensity Score Methods and Case Study
Hana Lee, US Food and Drug Administration, and Joo-Yeon Lee, US Food and Drug Administration

SC5: Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: Methodology and Implementation with R
Satrajit Roychoudhury, Pfizer Inc., and Keaven Anderson, Merck & Co., Inc.

SC6: Statistical Leadership: From Concepts to Practice
Rakhi Kilaru, PPD, and Lisa Lupinacci, Merck & Co., Inc.

Wednesday, September 23

Afternoon Short Courses

3:00 p.m. – 6:30 p.m.

SC7: Adaptive, Bayesian, and Complex Clinical Trials: What, Why, and How
Scott Berry, Berry Consultants, LLC

SC8: Leadership for Statisticians: The Bridge from Innovation to Practice
Gary Sullivan, Espirer Consulting LLC

SC9: Machine Learning for Statisticians
Junshui Ma, Merck & Co., Inc., and Andy Liaw, Merck & Co., Inc.

SC10: Statistical Designs and Strategies for Oncology Drug Development
Cong Chen, Merck & Co., Inc.

Key Dates